Share:
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision s proprietary asset, SPVN06, and further pipeline development
Paris, February 04, 2021 – SparingVision (the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, today announces the appointment of Dr Daniel C. Chung as Chief Medical Officer ( CMO ). Dr Chung brings a wealth of experience in successful ocular gene therapy development, having led the global medical strategy for ophthalmology at Spark Therapeutics ( Spark ), a leading rare disease gene therapy company, where he played a pivotal role in the clinical development and approval of Luxturna™, the first gene therapy to be approved in the US for a genetic disease. Spark was acquired by Roche in 2019 for $4.3 billion.
Renowned Pioneers in Ophthalmology Join SparingVision s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
Paris, January 29, 2021 - SparingVision (the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, today announces the strengthening of its Scientific Advisory Board ( SAB ) with the appointment of internationally renowned ophthalmology pioneers Dr. Paul A. Sieving, Professor of University of California Davis School of Medicine and the former Director of the US National Eye Institute, and Prof. Botond Roska, co-director of the Institute of Molecular and Clinical Ophthalmology Basel and Professor at the Medical and Science Faculty of the University of Basel.